This was splendid. Thanks for sharing your thoughts on this troubling new development. Once CAR T-cell treatments hit several home runs in AML, they became the bees knees for everything. Unfortunately, like everything else, they have their limitations and can cause horrific tumor lysis syndrome and cytokine storms (thank God for tocilizumab). I have not spent the time with the CAR T-cell studies I want to, but I too am convinced that the safety signal is real. Why would anyone give this product to a patient with smoldering myeloma? I don’t get it. Manni - I hope your clinical trial gets funded. It would answer questions and be a better addition to the present knowledge rather than some of the rubbish that passes for trials these days.
why - do you think - the FDA put out that overly broad t cell lymphoma statement for the commercial CAR t's a month or so ago? it was overly broad - accounted for approx 19 cases of t cell lymphoma out of approx 40,000 total doses.
I will share details publicly very soon- this is a 5 site multi-center trial with a decentralized platform allowing easy enrollment. If we get more funding, will expand.
I will share details publicly very soon- this is a 5 site multi-center trial with a decentralized platform allowing easy enrollment. If we get more funding, will expand.
This was splendid. Thanks for sharing your thoughts on this troubling new development. Once CAR T-cell treatments hit several home runs in AML, they became the bees knees for everything. Unfortunately, like everything else, they have their limitations and can cause horrific tumor lysis syndrome and cytokine storms (thank God for tocilizumab). I have not spent the time with the CAR T-cell studies I want to, but I too am convinced that the safety signal is real. Why would anyone give this product to a patient with smoldering myeloma? I don’t get it. Manni - I hope your clinical trial gets funded. It would answer questions and be a better addition to the present knowledge rather than some of the rubbish that passes for trials these days.
why - do you think - the FDA put out that overly broad t cell lymphoma statement for the commercial CAR t's a month or so ago? it was overly broad - accounted for approx 19 cases of t cell lymphoma out of approx 40,000 total doses.
Email me at g.mohyuddin@hci.utah.edu if you want more information.
I will share details publicly very soon- this is a 5 site multi-center trial with a decentralized platform allowing easy enrollment. If we get more funding, will expand.
What is the "smoldering" trial you guys are opening? Is it through the cooperative groups? Is it going to be open to docs in the community?
Email me at g.mohyuddin@hci.utah.edu if you want more information.
I will share details publicly very soon- this is a 5 site multi-center trial with a decentralized platform allowing easy enrollment. If we get more funding, will expand.
Happy Holidays guys! Love your Podcasts.
Do you think the AML MDS was from all the Fludara or other conditioning they got for their Car's